Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
RevMab
anti-Napsin-A (human), Rabbit Monoclonal (RM366)
Product Details | |
---|---|
Synonyms | Aspartyl Protease 4; ASP4; Napsin-1; TA01/TA02 |
Product Type | Recombinant Antibody |
Properties | |
Clone | RM366 |
Isotype | Rabbit IgG |
Source/Host | Rabbit |
Immunogen/Antigen | A peptide corresponding to the N-terminus of human Napsin-A. |
Application |
Immunohistochemistry (IHC): 1:500-1:1000 dilution |
Crossreactivity | Human |
Specificity |
This antibody reacts human Napsin-A. |
Purity | Protein A purified. |
Purity Detail | Protein A affinity purified from an animal origin-free culture supernatant. |
Concentration | N/A |
Formulation | Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. |
Isotype Negative Control | |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Accession Number | O96009 |
Declaration | Manufactured by RevMab Biosciences. |
Shipping and Handling | |
Shipping | BLUE ICE |
Long Term Storage | -20°C |
Handling Advice | Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Napsin-A is an aspartic proteinase that is abundantly expressed in normal lung and kidney tissue and is also frequently expressed in lung adenocarcinomas. Napsin-A has a role in processing pulmonary surfactant B protein produced by alveolar type II pneumocytes, therefore, it has been reported to be a good diagnostic marker for the confirmation of primary lung adenocarcinoma together with thyroid transcription factor 1 (TTF-1). Expression of napsin A is also observed in the fetal kidney and proximal tubules of the adult kidney, where it is most likely involved in protein catabolism. In neoplasms other than lung cancer, napsin A expression is most frequently observed in papillary renal carcinoma (79%), followed by other subtypes of renal cell carcinoma and thyroid carcinoma.